US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

11.52 -0.08 (-0.69%)
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Vir Biotechnology Appoints David Liu as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas Collaboration ↗
Via Chartmill
7 Bull Flag Setups Found With the ChartMill Stock Screener ↗
Via Chartmill
VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick ↗
Via Chartmill
News headline image
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript ↗
HDV combination therapy achieved 88% viral clearance, advancing toward Phase 3 readouts. 
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Q2 Earnings Call Highlights ↗
Vir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta... 
Via MarketBeat
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Chief Financial Officer Transition
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
News headline image
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗
Energy Vault Holdings develops modular, grid-scale energy storage systems for utilities and large-scale power users. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline. 
Via The Motley Fool
News headline image
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
From World Street Intelligence
Via GlobeNewswire
News headline image
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. ↗
Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir (VIR) Q1 2026 Earnings Call Transcript ↗
Vir (VIR) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
From Vir Biotechnology
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 ↗
Focused on infectious disease therapies, this biotech firm reported a notable insider sale amid a year of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
News headline image
Vir Biotechnology to Participate in Upcoming Investor Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >